home
Bringing New Horizons to Therapy

Investor Information

Event: November 16, 2011

EDAP TMS is presently accelerating adoption of HIFU therapy as a new standard of care for localized prostate cancer in Europe where the company is the clear market leader while securing US approval through an active FDA Clinical Study at leading urology centers.






IR Contact

Stock Information
NASDAQ : EDAP
Last Price : 2.54
Change : 0.31 down 10.877%
Day High : 2.76
Day Low : 2.45
Year High : 5.02
Year Low : 1.37
Volume : 110,800